Key result
Article provides scientific writing guidance without clinical data on GLP-1 receptor agonists.
Why the study?
GLP-1 receptor agonists are antihyperglycemic drugs that have emerged as potentially preventing cardiovascular events, motivating a pooled assessment of their effect on major cardiovascular outcomes.
Do glucagon-like-peptide-1 receptor agonists reduce major cardiovascular outcomes in patients across 12 randomized controlled trials?
Meta-Analysis
Do glucagon-like-peptide-1 receptor agonists reduce major cardiovascular outcomes in patients across 12 randomized controlled trials?
In a meta-analysis of 12 RCTs (n=82,669), GLP-1 receptor agonists significantly reduced cardiac death, all-cause mortality, stroke, and revascularization, without a statistically significant reduction in myocardial infarction or heart failure hospitalization.
GLP-1 receptor agonists reduce cardiac death; confirms benefit on major outcomes across 12 RCTs.
Glucagon-like-peptide-1 (GLP-1) receptor agonists are an antihyperglycemic group of drugs that have emerged as potentially preventing the risk of cardiovascular events. This meta-analysis assesses the effect of GLP-1 receptor agonists on cardiovascular outcomes. A detailed search of existing literature was based on MEDLINE, the Cochrane Library, Embase, and ClinicalTrials.gov. The search included all the studies from inception to February 2026. Statistical analyses were performed using the RevMan software, and a random-effects model was used to conduct the meta-analysis. Data were represented via forest plots, and dichotomous outcomes were evaluated using the Mantel-Haenszel method. This meta-analysis includes 12 randomized control trials (RCTs) with 82,669 patients. The analysis showed that GLP-1 receptor agonists reduce risk of cardiac death [relative risk (RR): 0.89, 95% confidence interval (CI): 0.82-0.96, p=0.003, I²=0%], all-cause mortality (RR: 0.88, 95% CI: 0.84-0.93, p<0.00001, I²=0%), stroke (RR: 0.85, 95% CI: 0.77-0.94, p=0.001, I²=0%), non-fatal stroke (RR: 0.87, 95% CI: 0.79-0.96, p=0.005, I²=0%) and revascularization (RR: 0.82, 95% CI: 0.72-0.95, p=0.007, I²=59%). There was no statistically significant reduction in myocardial infarction (MI) (RR: 0.92, 95% CI: 0.84-1.01, p=0.09, I²=42%), fatal MI (RR: 1.15, 95% CI: 0.80-1.66, p=0.44, I²=0%), non-fatal MI (RR: 0.91, 95% CI: 0.82-1.01, p=0.09, I²=51%), fatal stroke (RR: 0.75, 95% CI: 0.55-1.00, p=0.05, I²=0%), heart failure hospitalization (RR: 0.94, 95% CI: 0.85-1.03, p=0.20, I²=17%), or hospitalization for unstable angina (RR: 0.97, 95% CI: 0.85-1.12, p=0.71, I²=0%). This meta-analysis demonstrates that GLP-1 receptor agonists have a significant impact on cardiovascular death. More thorough RCTs with longer follow-up periods are required to completely understand the possible cardiovascular advantages of GLP-1 receptor agonists.
No takes yet. Share an insight, caveat, or question.
Saleem et al. (2026) reported a meta-analysis. Glucagon-like-peptide-1 receptor agonists was evaluated on Major cardiovascular outcomes. Glucagon-like-peptide-1 receptor agonists were listed in the title, but the provided text contains only a guide on writing scientific papers with no clinical data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: